Trial intelligence / Profile preview

SURVEYOR-II in chronic hepatitis C genotypes 2-6

2014-002927-90Phase 2Completed

Sponsor: AbbVie Inc.
Start: Oct 2014
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, randomised, open-label trial in chronic hepatitis C (CHC) comparing ABT-493 + ABT-530 with ABT-493 + ABT-530 + ribavirin (2 arms). Primary endpoint: SVR12. Started Oct 2014; status: completed.

Drugs

glecaprevirribavirin

Conditions

chronic hepatitis C (CHC)

Beyond the preview

Go deeper on 2014-002927-90.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2014-002927-90.